

PTO/SB/21 (09-04)

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

Total Number of Pages In This Submission

Application Number	10/506,748	RECEIVED
Filing Date	September 3, 2004	CENTRAL FAX CENTER
First Named Inventor	Alan Martin Birch	
Art Unit	1625	FEB 21 2006
Examiner Name	Not Yet Assigned	
Attorney Docket Number	100662-1P US	

8

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Annotated Application Data Sheet
<input type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	Supplemental Application Data Sheet
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	AstraZeneca	
Signature		
Printed name	Lucy Clare Padgett	
Date	21 - FEB - 2006	Reg. No. L0074

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature	
Typed or printed name	Lucy Clare Padgett
Date	February 21, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

FEB 21 2006

Application No.: 10/506,748	Applicant: Birch et al
371 Filing Date: September 3, 2004	Attorney Docket No.: 100662-1P US
Examiner: Not yet assigned	Group Art Unit : 1625
Customer No.: 44992	Confirmation No.: 6588
Title: INDOLE-AMIDE DERIVATIVES AND THEIR USE AS GLYCOGEN PHOSPHORYLASE INHIBITORS	

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office (571-273-8300) on February 21, 2006

Signature
Lucy C. Padget

Mail Stop
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RE: SUPPLEMENTAL APPLICATION DATA SHEET

Sirs,

The Applicants submit herewith a Supplemental Application Data Sheet to amend inventorship details.

In addition to the above changes the Application Data Sheet now reflects the recent changes to the address for correspondence and representative information.


The Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No.: 100662-1P US.

AstraZeneca R&D Boston
A business unit of AstraZeneca Pharmaceuticals LP
35 Gatehouse Drive
Waltham MA 02451

Tel +1 781-839-4000
Fax +1 781-839-4500

1

Respectfully submitted,



Name: Lucy C. Padget
Dated: February 21, 2006
Reg. No.: L0074
Phone No.: 1 781 839 4182
Global Intellectual Property, Patents
AstraZeneca R&D Boston
35, Gatehouse Drive
Waltham, MA 02451

Enclosures: Annotated Application Data Sheet
Supplemental Application Data Sheet
Transmittal Form

SUPPLEMENTAL APPLICATION DATA SHEET**Application Information**

Application No.: 10/506,748
371 Filing Date: September 3, 2004
Application Type: Regular
Subject Matter: Utility
Suggested Group Art Unit: N/A
CD-ROM or CD-R?: None
Sequence submission?: None
Computer Readable Form (CRF)??: No
Title: INDOLE-AMIDE DERIVATIVES AND
THEIR USE AS GLYCOGEN
PHOSPHORYLASE INHIBITORS
Attorney Docket Number: 100662-1P US
Request for Early Publication?: No
Request for Non-Publication?: No
Small Entity?: No
Petition included?: No
Secrecy Order in Parent Appl.??: No

Applicant Information

Applicant Authority Type: Inventor
Primary Citizenship Country: United Kingdom
Status: Full Capacity
Given Name: Alan
Middle Name: Martin
Family Name: Birch
City of Residence: Cheshire
Country of Residence: United Kingdom
Street of mailing address: AstraZeneca R&D Alderley; Mereside
Alderley Park; Macclesfield

City of mailing address::	Cheshire
Country of mailing address::	United Kingdom
Postal or Zip Code of mailing address::	SK10 4TG
Applicant Authority Type::	Inventor
Primary Citizenship Country::	United Kingdom
Status::	Full Capacity
Given Name::	Andrew
Middle Name::	David
Family Name::	Morley
City of Residence::	Cheshire
Country of Residence::	United Kingdom
Street of mailing address::	AstraZeneca R&D Alderley; Mereside Alderley Park; Macclesfield
City of mailing address::	Cheshire
Country of mailing address::	United Kingdom
Postal or Zip Code of mailing address::	SK10 4TG

Correspondence Information

Correspondence Customer Number:: 44992

Representative Information

Representative Customer Number:: 44992

Domestic Priority Information

Application::	Continuity Type::	Parent Application::	Parent Filing Date::
This Application	National Stage of	PCT/GB03/00893	03/04/03

Foreign Priority Information

Country::	Application number::	Filing Date::	Priority Claimed::
United Kingdom	0205162.1	03/06/02	Yes

Assignee Information

Assignee name:: AstraZeneca AB
Street of mailing address:: R&D Headquarters
Global Intellectual Property Patents
City of mailing address:: Södertälje
Country of mailing address:: Sweden
Postal or Zip Code of mailing address:: SE-151 85

ANNOTATED ORIGINAL

Supplemental

Application Data Sheet

Application Information

APPLICATION NO. and 371 FILING DATE 10/506,748 Sept. 3, 2004 ←
Application Type:: Regular
Subject Matter:: Utility
Suggested Group Art Unit:: N/A
CD-ROM or CD-R?:: None
Sequence submission?:: None
Computer Readable Form (CRF)?:: No
Title:: INDOLE-AMIDE DERIVATIVES AND
THEIR USE AS GLYCOGEN
PHOSPHORYLASE INHIBITORS

Attorney Docket Number:: ASZD-P01-662 100662-1 P US ←
Request for Early Publication?:: No
Request for Non-Publication?:: No
Small Entity?:: No
Petition included?:: No
Secrecy Order in Parent Appl.?:: No

Applicant Information

Applicant Authority Type:: Inventor
Primary Citizenship Country:: United Kingdom
Status:: Full Capacity
Given Name:: Alan Martin ←
Middle Name:: MARTIN ←
Family Name:: Birch ←
ADDRESS ADDED ←
Inventor

Applicant Authority Type:: Inventor
Primary Citizenship Country:: United Kingdom
Status:: Full Capacity
Given Name:: Andrew
Middle Name:: David

Page #1

Entered 09/03/04

02/21/2006; Supplemental; 09/03/2004

Family Name:: Morley
City of Residence:: Cheshire
Country of Residence:: United Kingdom
Street of mailing address:: AstraZeneca R&D Alderley; Mereside
Alderley Park; Macclesfield
City of mailing address:: Cheshire
Country of mailing address:: United Kingdom
Postal or Zip Code of mailing address:: SK10 4TG

Correspondence Information

Correspondence Customer Number:: 28120 44992 4

Representative Information

Representative Customer Number:: 28120 44992 4

Domestic Priority Information

Application::	Continuity Type::	Parent Application::	Parent Filing Date::
This Application	National Stage of	PCT/GB03/00893	03/04/03

Foreign Priority Information

Country::	Application number::	Filing Date::	Priority Claimed::
United Kingdom	0205162.1	03/06/02	Yes

Assignee Information

Assignee name:: AstraZeneca AB
Street of mailing address:: R&D Headquarters
Global Intellectual Property Patents
City of mailing address:: Södertälje
Country of mailing address:: Sweden
Postal or Zip Code of mailing address:: SE-151 85

12/21/2006; Page #2 Initials: 09/03/04
Supplemental: 09/03/2004

-2608626.1-